New Studies Highlight Potential for T2Bacteria and T2Candida Panels to Improve Outcomes and be Cost-Effective for Sepsis Pati...
June 06 2019 - 7:30AM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development
of innovative diagnostic products for critical unmet needs in
healthcare, announced today the publication of two independent,
peer-reviewed studies highlighting the potential of the T2Bacteria
and T2Candida Panels to improve outcomes and be cost-effective for
a wide range of clinical scenarios. The most recent study, titled
“Cost-effectiveness of molecular diagnostic assays for the therapy
of severe sepsis and septic shock in the emergency department,” was
published in the online journal PLOS ONE. This follows another
study titled “Cost-effectiveness of rapid diagnostic assays that
perform directly on blood samples for the diagnosis of septic
shock” that was published in the journal Diagnostic Microbiology
and Infectious Disease.
These studies examined the cost-effectiveness of using two blood
culture sets in conjunction with rapid molecular diagnostic assays,
including the direct-from-blood T2Bacteria and T2Candida Panels,
which are the only U.S. Food and Drug Administration (FDA) cleared
diagnostic tests that detect the species-specific pathogens
associated with sepsis (“bundle approach”), versus the use of two
sets of blood cultures only, for patients presenting in the
Emergency Department or the medical Intensive Care Unit (ICU) with
severe sepsis or septic shock. The studies concluded that:
- The bundle approach provided more effective antibiotic therapy
than blood culture alone.
- The bundle approach was cost effective as compared to blood
culture alone, when considering cost savings for deaths averted by
a direct-from-sample molecular diagnostic test.
- The effectiveness of the bundle approach is expected to
maximize when used at time of presentation of septic patients to
the Emergency Department and in hospital settings with high
prevalence of drug resistant pathogens and high rates of
inappropriate empiric antibiotic therapy.
“This study provides a detailed analysis of the potential
clinical and cost-savings benefits of implementing rapid molecular
diagnostics assays of which the T2Bacteria and T2Candida Panels are
the only FDA-cleared products in the market, in patients with
severe sepsis or septic shock in the medical ICU and emergency
department,” said John McDonough, president and chief executive
officer. “This is aligned with the real-world results reported by
our customers, which includes actionable results in as little as
3-5 hours, allowing for appropriate adjustment of antibiotic
therapy, or de-escalation of therapy in patients with a negative
result. This rapid result uniquely provided by our products and
benefits patient care can lead to cost-savings and supports
improved antimicrobial stewardship.”
The cost-effectiveness conclusions from the study align with the
real-world results reported by T2 customers. This utilization also
includes patients that present in the hospital with symptoms of a
blood stream infection (BSI) but are not in severe sepsis or septic
shock. The T2Bacteria and T2Candida Panels provide rapid diagnostic
results for these patients, allowing clinicians to ensure that
their patients are on effective antimicrobial therapy in order to
optimize outcomes. These improved clinical outcomes also have the
potential to significantly improve cost savings as has been
independently demonstrated by many T2 customers.
The corresponding author of the studies is Eleftherios
Mylonakis, of the Infectious Diseases Division, Warren Alpert
Medical School of Brown University, Rhode Island Hospital.
About T2 Biosystems T2 Biosystems, a
leader in the development and commercialization of innovative
medical diagnostic products for critical unmet needs in healthcare,
is dedicated to improving patient care and reducing the cost of
care by helping clinicians effectively treat patients faster than
ever before. T2 Biosystems’ products include the T2Dx® Instrument,
T2Candida® Panel, and T2Bacteria® Panel and are powered by the
proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems
has an active pipeline of future products, including products for
the detection of additional species and antibiotic resistance
markers of sepsis pathogens, and tests for Lyme disease.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, without limitation,
statements regarding additional patients, timing of testing
patients, anticipated product benefits, strategic priorities,
product expansion or opportunities, growth expectations or targets,
timing of FDA filings or clearances and anticipated operating
expenses, as well as statements that include the words “expect,”
“intend,” “plan”, “believe”, “project”, “forecast”, “estimate,”
“may,” “should,” “anticipate,” and similar statements of a future
or forward looking nature. These forward-looking statements are
based on management's current expectations. These statements are
neither promises nor guarantees, but involve known and unknown
risks, uncertainties and other important factors that may cause
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements, including,
but not limited to, (i) any inability to (a) realize anticipated
benefits from commitments, contracts or products; (b) successfully
execute strategic priorities; (c) bring products to market; (d)
expand product usage or adoption; (e) obtain customer
testimonials; (f) accurately predict growth assumptions; (g)
realize anticipated revenues; (h) incur expected levels of
operating expenses; or (i) increase the number of high-risk
patients at customer facilities; (ii) failure of early data to
predict eventual outcomes; (iii) failure to make or obtain
anticipated FDA filings or clearances within expected time frames
or at all; or (iv) the factors discussed under Item 1A. "Risk
Factors" in the company's Annual Report on Form 10-K for the year
ended December 31, 2018, filed with the U.S. Securities and
Exchange Commission, or SEC, on March 14, 2019, and other filings
the company makes with the SEC from time to time. These and
other important factors could cause actual results to differ
materially from those indicated by the forward-looking statements
made in this press release. Any such forward-looking statements
represent management's estimates as of the date of this press
release. While the company may elect to update such forward-looking
statements at some point in the future, unless required by law, it
disclaims any obligation to do so, even if subsequent events cause
its views to change. Thus, no one should assume that the Company’s
silence over time means that actual events are bearing out as
expressed or implied in such forward-looking statements.
These forward-looking statements should not be relied upon as
representing the company's views as of any date subsequent to the
date of this press release.
Media Contact: Gina Kent, Vault
Communicationsgkent@vaultcommunications.com 610-455-2763
Investor Contact: Zack Kubow, W2O Group
zkubow@w2ogroup.com 415-658-6436
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024